Rockville, Maryland — September 29, 2026: The global movement disorder market is valued at USD 1,004.4 million in 2026 and is projected to reach USD 3,009.9 million by 2036, expanding at a CAGR of 11.6% during the forecast period. According to Fact.MR, the market is being shaped by rising Parkinson disease prevalence among aging populations, broader access to specialist neurological care, advances in targeted dopaminergic therapies, and development of adaptive deep brain stimulation systems.

Get detailed market forecasts, competitive benchmarking, and pricing trends:https://www.factmr.com/connectus/sample?flag=S&rep_id=329

A major source of demand is the growing number of patients requiring long-term pharmacological and interventional management of movement disorders. Fact.MR identifies the increasing incidence of Parkinson disease in older populations as a central market driver. At the same time, next-generation dopaminergic agents with improved receptor selectivity are being developed to address limitations associated with existing therapies. Advances in deep brain stimulation, including systems capable of sensing neural signals and adjusting stimulation, are also expanding treatment options for patients whose symptoms are not adequately controlled by medication. Pharmaceutical investment in disease-modifying approaches, including alpha-synuclein-targeting therapies and gene therapy, is adding another potential avenue for future market development.

Dopaminergic Agents Maintain the Largest Therapeutic Class Share

Dopaminergic agents account for 44.6% of the therapeutic class segment in 2026, reflecting their established role in managing motor symptoms associated with Parkinson disease. Levodopa/carbidopa combinations remain central to treatment, while dopamine agonists and newer receptor-selective candidates are expanding the therapeutic landscape. Oral therapies represent 46.1% of the route-of-administration segment, supported by their compliance advantages and accessibility through prescribing channels. Parkinson disease itself represents 58.9% of disease indication value in 2026, with its chronic progressive nature generating prolonged treatment requirements and increasing therapeutic complexity over time.

Specialty neurology clinics account for 37.8% of end-user share because diagnosis and management of movement disorders depend heavily on specialist expertise. Pharmacological therapy represents 49.3% of therapy type share, while neuromodulation is advancing as adaptive DBS technology develops. The report also identifies disease-modifying therapies targeting alpha-synuclein aggregation and neuroinflammation, gene therapy approaches, and investment in neurological infrastructure across emerging markets as significant opportunity areas.

China Leads Country Growth as European Markets Maintain Steady Expansion

China records the highest CAGR among the countries covered in the report at 13.0% through 2036. Growth is associated with expansion of hospital neurology departments, increasing Parkinson disease diagnosis rates, centralized drug purchasing through the VBP program, and domestic pharmaceutical development. Hospital expansion in Tier 2 and Tier 3 cities is also improving access to neurology specialists, while technology self-sufficiency policies are encouraging domestic development of neuromodulation devices.

Germany is projected to expand at an 11.3% CAGR, supported by established university hospital neurology networks, DBS implantation capabilities, the GKV reimbursement system, and EU regulatory frameworks for neuromodulation devices and therapeutics. UK movement disorder market growth stands at 11.2% CAGR, with the country included among Europe's steadily expanding markets alongside established neurological care infrastructure and DBS center networks.

Other markets also register substantial growth. India is projected to expand at 12.6%, supported by wider neurological care access and private hospital investment, while the USA is expected to grow at 12.1%, reflecting pharmaceutical adoption, specialist care, and DBS program development. Japan records a 10.9% CAGR, with its aging population sustaining demand for long-term movement disorder treatment.

Leading Companies Focus on Pharmacotherapy and Neuromodulation

The competitive landscape includes major healthcare companies spanning pharmaceutical and medical device solutions. Key players identified by Fact.MR include AbbVie Inc., Medtronic plc, Boston Scientific Corporation, and Abbott Laboratories, with additional companies including UCB S.A. and Teva Pharmaceutical Industries. AbbVie is active in Parkinson disease pharmacotherapy and has a growing movement disorder pipeline, while Medtronic and Boston Scientific compete in neuromodulation through DBS portfolios and adaptive stimulation technologies.

Unlock 360° insights for strategic decision making and investment planning:

With the market expected to create an absolute dollar opportunity of USD 2,005.5 million between 2026 and 2036, advances in targeted pharmacotherapy, adaptive neuromodulation, specialist care infrastructure, and emerging disease-modifying approaches are expected to remain important areas of development. The complete Fact.MR report provides detailed market forecasts, segmentation, country analysis, competitive benchmarking, and strategic insights for the 2026–2036 period.

Explore More Related Studies Published by Fact.MR Research

Laser Cancer Therapy Market

Cryopreservation & Fertilization Media Market

Esophageal Stents Market

About Fact.MR

Fact.MR is a global market research and consulting firm, trusted by Fortune 500 companies and emerging businesses for reliable insights and strategic intelligence. With a presence across the U.S., UK, India, and Dubai, we deliver data-driven research and tailored consulting solutions across 30+ industries and 1,000+ markets. Backed by deep expertise and advanced analytics, Fact.MR helps organizations uncover opportunities, reduce risks, and make informed decisions for sustainable growth.

- Contact Us -
11140 Rockville Pike, Suite 400, Rockville,
MD 20852, United States
Tel: +1 (628) 251-1583 | [email protected]